TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02853136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Fluvoxamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Fluvoxamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Fluvoxamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306 - Powder for oral solution (PfOS)
Description: BI 409306 - Powder for oral solution (PfOS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306 - Powder for oral solution (PfOS)
Description: BI 409306 - Powder for oral solution (PfOS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306 - film coated tablet
Description: BI 409306 - film coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306 - film coated tablet
Description: BI 409306 - film coated tablet
Study: NCT02167867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lay End Users
Description: Lay End Users administer 40 minutes of treatment with the ZERONA Z6 to the waist, hips and thighs (20 minutes to the front side and 20 minutes to the back side) of a Treatment Subject, 6 times evenly spaced across two consecutive weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment Subject Group
Description: Treatment subject received 6 40-minute evenly spaced treatments to the hips, waist and thighs (20 minutes to the front side and 20 minutes to the back side) with the ZERONA Z6 over 2 consecutive weeks. The ZERONA Z6 contains 6 17.25 milliWatts (mW) 635 nanometers (nm) laser diodes.
Study: NCT01980264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harmonic Generation Microscopy
Description: Harmonic Generation Microscopy is a nonlinear optical microscopy.
Study: NCT03424343

Intervention type: OTHER
Intervention: Questionnaire bundle
Description: Questionnaires on identity formation and psychosocial functioning, assessed and reported at baseline, one year later, two years later, and five years later.

Intervention type: OTHER
Intervention: Obtaining information from survivors' medical file
Description: After obtaining informed consent, we will access the medical file of participants to obtain information on the diagnosis, time of diagnosis, treatment duration, type of treatment, and relapse (when applicable).
Study: NCT05210543

Intervention type: OTHER
Intervention: not applicable, observational study
Description: Patients do not receive intervention; observational study
Study: NCT03877549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Additional of two different doses of dexamethasone via the epidural catheter during surgical closure after cesarean section

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Additional of two different doses of dexamethasone via the epidural catheter during surgical closure after cesarean section

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Additional of two different doses of dexamethasone via the epidural catheter during surgical closure after cesarean section
Study: NCT02331303

Intervention type: OTHER
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Xofigo was approved in the US and EU for the following indication: Xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. Xofigo is contraindicated in women who are or may become pregnant.
Study: NCT02997085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Live-Action 360° Video Virtual Reality
Description: 360° Video Virtual Reality (VVR) is made by filming with multiple HD cameras carefully arranged to capture all angles in a 360° area of a live action event. Then those angles are stitched together in post-production into a 360-degree texture sphere and the sphere is then mapped to the head tracker on the users head mounted display (HMD). Leading to the effect that when a user turns his head, the user's view of the live action video footage turns with them in real time allowing the user to look around anywhere in the 360 degrees of filmed footage of the live action event. Participants randomized to the Live-Action 360° VVR group will be outfitted with a Samsung Gear VR HMD and will view a 9-minute live-action 360° VVR video. The 9 minutes of footage will be alternating 30 second clips of central Texas locations.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CGI 360° Video Virtual Reality
Description: Participants randomized to the CGI 360° VVR condition will also be outfitted with a Samsung Gear VR head mounted display. Participants will view the same content for the same duration as in the Live-Action 360° VVR condition, but the footage will be animated instead of live-action footage.
Study: NCT03592355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Visit
Description: Clinicians will have a synchronous video visit with their patients.
Study: NCT02129972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colon videocapsule endoscopy (PillCam colon 2)
Description: This is a simple blind (blind for the lecture of the CVC record) study to evaluate the diagnostic value of the colon capsule endoscopy for the detection and the control of colon lesions, the feasibility, tolerance and safety of the CVC compared to the conventional colonoscopy under general sedation in children presented with Inflammatory Bowel Disease.~Over one week, the patient will undergo two exams (CVC and colonoscopy under general sedation). The exams will be done by two different physicians.~In order to assess the tolerance, after the completion of both exams, the patients will be asked to answer a comfort score questionnaire.~In order to assess the safety of the CVC, the patients will have a follow-up for adverse events over a 3 weeks period after completion of the CVC and only if the colon video capsule was not recovered during the conventional colonoscopy.
Study: NCT02626884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Study: NCT03921567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and in perioperative and postoperative period will be given lidocaine 1.5mg / kg / h-1, continuously during surgery and 48 hours after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and in perioperative and postoperative period will be given lidocaine 1.5mg / kg / h-1, continuously during surgery and 48 hours after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride and Ketamine
Description: at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and ketamine 0.15mg / kg / , bolus, i.v .; lidocaine will continue during the operation and in the postoperative period with a dose of 1.5mg / kg / h-1, continuously, during the operation and 48 hours after the operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: will be given opioids during surgery, and opioids and nonsteroid antiinflammatory agents will be given 48 hours after surgery.
Study: NCT01927913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD602
Description: 32, 50 or 75 mg/kg/day BID, capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferasirox
Description: Per approved country specific label
Study: NCT06042816

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free-opioid anesthesia
Description: Free opioid anesthesia (FOA) has been used in many countries around the world, making use of multimodal analgesia therapy which includes hypnotics, N-methyl-D-aspartate (NMDA) antagonists, local anesthetics and anti-inflammatory agents and sympathetic block in surgery. This method was demonstrated to contribute to enhanced recovery after surgery (ERAS). The use of long-acting local anesthetics also enhances postoperative pain relief. As a result, the concept of balanced anesthesia now has a change in three basic components: hypnotics, muscle relaxants and sympathomimetic inhibitors

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: opioid anesthesia
Description: Opioids have been used as one of three basic components of balanced anesthesia, including anesthetic drugs, pain relievers, and neuromuscular blockade agents (opioid anesthesia). Opioids not only facilitate deep anesthesia but also create the most favorable conditions for surgeries. Fentanyl is a potent opioid used to control pain, reduce the dose of sympathomimetic inhibitors and maintain hemodynamic stability. However, several common side effects of fentanyl are well known: nausea and vomiting, constipation, urinary retention, headache, pruritus, rash, histamine release, biliary spasm and respiratory depression, the most severe adverse effect
Study: NCT01868412

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abilar 10% resin salve
Description: The resin salve may be spread directly onto the wound, after which the area is covered with a bandage suitable for local wound care. The bandage prohibits salve from moving away from the wound area. If the skin condition is more widespread or contains cavities or fistulae, the salve may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the degree of infection and amount of wound secretion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activon Tube 25 g
Description: Wound care with the medical honey is carried out in the same manner than the resin salve treatment: honey may be spread directly onto the wound and the wound area is covered with a bandage suitable for local wound care. Similarly, if the skin condition is more widespread or wound contains cavities or fistulae, the medical honey may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the severity of infection and amount of wound secretion.
Study: NCT00104884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depsipeptide
Description: Given IV
Study: NCT02806661

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vagus nerve-preserving Robot-assisted Gastrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Robot-assisted Gastrectomy
Study: NCT03715907

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Incentives for gap closure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Incentives for gap closure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Incentives for gap closure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Incentives for gap closure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Incentives for gap closure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Incentives for gap closure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Information on care gap and closure process.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Information on care gap and closure process.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Information on care gap and closure process.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Information on care gap and closure process.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Information on care gap and closure process.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Information on care gap and closure process.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Information on care gap and closure process.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Information on care gap and closure process.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Information on care gap and closure process.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Information on care gap and closure process.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Information on care gap and closure process.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Information on care gap and closure process.
Study: NCT02294864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Pulsed Radiofrequency
Description: Pulsed Radiofrequency

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Study: NCT04831346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low level laser
Description: 940 nm wavelength with 0.2 W output power and 2 J energy applied for 10 seconds with an energy density of 2.5 J/cm2.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft occlusive splint
Description: A vacuum-formed soft occlusal splint made from a 2-mm-thick elastic rubber sheets.~Participants are instructed to always wear the splint except during mealtimes and oral hygiene.
Study: NCT03298737

Intervention type: BEHAVIORAL
Intervention: Covert Spatial Attention
Description: During behavioral sessions, subjects will sit in a dark room and view a video monitor placed at the minimum of 57 cm distance away from the subject. Staff will be present throughout all the testing to assist the subject and monitor equipment that is used for tracking their eye position. Subjects will be asked to maintain their heads in a stable position of rest in order to insure accurate tracking of their eye position. To stabilize their head, subjects will either use a chin rest in which they position their chin on a soft pad mounted in front of a video screen, or they may use a bite bar.
Study: NCT03740113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kids SipSmartER
Description: Kids SIPsmartER is grounded by the Theory of Planned Behavior as well as health literacy, media literacy, numeracy, and public health literacy concepts
Study: NCT04256941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abemaciclib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribociclib
Description: Given PO
Study: NCT04115033

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Alpha-stim
Description: The device for both groups is the Alpha-stim, a FDA-approved device similar to the Military Field Stimulator (MFS/Neuro-Stim System), a cranial electrical stimulation (CES) device.
Study: NCT00472719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV027-00-VP
Description: Adenoviral vector booster vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV027-00-VP
Description: Adenoviral vector booster vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV027-00-VP
Description: Adenoviral vector booster vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV038-00-VP
Description: Adenovirus vector booster vaccine
Study: NCT03278509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Please see the section above.
Study: NCT03964441

Intervention type: BIOLOGICAL
Intervention: Invasive fetal sampling, blood sampling of mother and father
Description: to perform an exome sequencing analysis in trio

Intervention type: BIOLOGICAL
Intervention: Invasive fetal sampling, blood sampling of mother and father
Description: to perform an exome sequencing analysis in trio
Study: NCT00472719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV038-00-VP
Description: Adenovirus vector booster vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVADV038-00-VP
Description: Adenovirus vector booster vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVDNA044-00-VP
Description: Experimental, multiclade, multigene HIV DNA vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVDNA044-00-VP
Description: Experimental, multiclade, multigene HIV DNA vaccine
Study: NCT03964441

Intervention type: BIOLOGICAL
Intervention: blood sampling from the mother to recover the circulating cell free fetal DNA
Description: to perform a sequencing analysis of the genome of circulating free fetal DNA
Study: NCT01928173

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Abbreviated cognitive behavioral therapy
Description: see arm description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep education/sleep hygiene
Description: see arm description
Study: NCT03948243

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Licorice
Description: Experimental :G. glabra Licorice extract: 2 gelatin capsules (75 mg) per day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam 2 MG
Description: probe substrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine 100 MG
Description: probe substrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolbutamide 250 mg
Description: probe substrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 30mg
Description: probe substrate
Study: NCT01706822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Covidien Radial Reload Stapler with Tri-Staple Technology
Description: Case series of patients arlaedy selected to undergo a laparoscopic LAR using the Radial Reload stapler
Study: NCT05073211

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PDT
Description: A 630 nm red light and a 520 nm green light of the light-emitting diode (LED) device (Nouvo-GB®) with an intensity of 35 mW⁄cm2 was simultaneously illuminated for 10 minutes (a total light dose of 21 J/cm2). Participants received a total of four treatments at 1-week intervals and were followed up 1 and 4 weeks after the last treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PDT
Description: A 630 nm red light and a 520 nm green light of the light-emitting diode (LED) device (Nouvo-GB®) with an intensity of 35 mW⁄cm2 was simultaneously illuminated for 10 minutes (a total light dose of 21 J/cm2). Participants received a total of four treatments at 1-week intervals and were followed up 1 and 4 weeks after the last treatment.
Study: NCT03531359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIBD
Description: Table-based Interactive Distraction using video-games will be used to prove efficacy in preventing preoperative anxiety.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Administration of midazolam oral or rectal 30 minutes to one hour prior to transfer to the theater.
Study: NCT00706693

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ingestion of BD glucose tablets (TM)
Description: Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with BD glucose tablets by giving 10g of glucose in children 10 and under. Children and teens over 10 will receive 15g of glucose.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ingestion of Skittles (TM)
Description: Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Skittle by giving 10g of sucrose in children 10 and under. Children and teens over 10 will receive 15g of sucrose.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ingestion of Fruit to Go (TM)
Description: Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Fruit to Go by giving 10g of fructose in children 10 and under. Children and teens over 10 will receive 15g of fructose.
Study: NCT03836417

Intervention type: DIAGNOSTIC_TEST
Intervention: Microarray analysis
Description: Microarray analysis to identify gene expression profiles that distinguish IPF from NSIP
Study: NCT03904732

Intervention type: DRUG
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: Low-dose acetylsalicylic acid, Aspirin (75-150 mg)

Intervention type: DRUG
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: Low-dose acetylsalicylic acid, Aspirin (75-150 mg)

Intervention type: DRUG
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: Low-dose acetylsalicylic acid, Aspirin (75-150 mg)

Intervention type: DRUG
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: Low-dose acetylsalicylic acid, Aspirin (75-150 mg)
Study: NCT00968864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS® (T cell depletion)
Description: Stem cells will be collected from donors after they receive Granulocyte colony-stimulating factor (G-CSF). The cells will be processed using the CliniMACS device to select for CD34+ stem cells and to deplete T cells. Recipients will receive conditioning therapy that is based on their disease type and then receive the CD34+ stem cells.
Study: NCT03468101

Intervention type: OTHER
Intervention: Pulmonary Function Testing
Description: Pulmonary Function Testing, Cardiopulmonary exercise testing, 6 Minute walk test, Thoracic CT

Intervention type: OTHER
Intervention: Pulmonary Function Testing
Description: Pulmonary Function Testing, Cardiopulmonary exercise testing, 6 Minute walk test, Thoracic CT
Study: NCT02407795

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: conventional radiotherapy
Description: 1x8Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiotherapy
Description: 1x20Gy or equivalent dose fractionation schedule
Study: NCT04925726

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Land based exercise
Description: The patients who had land based exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water based exercise
Description: The patients who had water based exercise